Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium selenate is an inorganic sodium salt containing selenium in the form of the selenate ion. It is used as a source of selenium in dietary supplements and has been investigated as a potential pharmaceutical agent. Mechanistically, sodium selenate acts as a specific activator (agonist) of protein phosphatase 2A (PP2A), leading to dephosphorylation of tau protein and reduction in hyperphosphorylated tau levels. This mechanism underlies its disease-modifying potential for neurodegenerative diseases such as Alzheimer's disease and temporal lobe epilepsy, where it has shown efficacy in reducing neurodegeneration, improving cognitive function, and decreasing seizure severity in preclinical models and early clinical trials[1][4][5][6][8]. Sodium selenate also has roles as an anticonvulsant and fertilizer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium selenate.